skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Free E-Journal (出版社公開部分のみ） remover tipo de recurso: Anais de Congresso remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Proceedings of Peer-reviewed and selected articles from Turgut Ozal University Faculty of Medicine 7th International Student Congress
Proceedings of Peer-reviewed and selected articles from Turgut Ozal University Faculty of Medicine 7th International Student Congress
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Proceedings of Peer-reviewed and selected articles from Turgut Ozal University Faculty of Medicine 7th International Student Congress

Ceylan, Furkan S

Clinical and investigative medicine, 2016, Vol.39 (6), p.27491-27491 [Periódico revisado por pares]

Canada

Texto completo disponível

Citações Citado por
2
750 TWT-101: a first-in-clinic, phase 1/2 study of CFI-402411, a hematopoietic progenitor kinase-1 (HPK1) inhibitor, as a single agent and in combination with pembrolizumab in subjects with advanced solid malignancies
750 TWT-101: a first-in-clinic, phase 1/2 study of CFI-402411, a hematopoietic progenitor kinase-1 (HPK1) inhibitor, as a single agent and in combination with pembrolizumab in subjects with advanced solid malignancies
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

750 TWT-101: a first-in-clinic, phase 1/2 study of CFI-402411, a hematopoietic progenitor kinase-1 (HPK1) inhibitor, as a single agent and in combination with pembrolizumab in subjects with advanced solid malignancies

Papadopoulos, Kyriakos ; Fu, Siqing ; Hamilton, Erika ; Spira, Alexander ; Scott, Laurie ; Wang, Judy ; Ma, Brigette ; Spreafico, Anna ; Sharma, Manish ; Chu, Quincy ; Bray, Mark ; Michelson, Glenn ; Chen, Dih-Yih ; Nguyen, Linh ; Roberts-Thomson, Emily ; Hamid, Omid

Journal for immunotherapy of cancer, 2022, Vol.10 (Suppl 2), p.A783-A783 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
3
052: BARRIERS TO HEALTH RESEARCH USE IN KENYA AND MALAWI
052: BARRIERS TO HEALTH RESEARCH USE IN KENYA AND MALAWI
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

052: BARRIERS TO HEALTH RESEARCH USE IN KENYA AND MALAWI

Oronje, Rose N ; Murunga, Violet I ; Longwe-Ngwirai, Abiba L ; Mushani, Nissily M ; Abisi, Jones A ; Zulu, Eliya M

BMJ open, 2015, Vol.5 (Suppl 1), p.bmjopen-2015-forum2015abstracts.52 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
4
O33 Qualitative story completion: an innovative method with exciting potential for health research
O33 Qualitative story completion: an innovative method with exciting potential for health research
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

O33 Qualitative story completion: an innovative method with exciting potential for health research

Braun, Virginia ; Moller, Naomi ; Clarke, Victoria

BMJ open, 2019, Vol.9 (Suppl 1), p.A13-A13 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
5
1272 Probabilistic mixture models improve calibration of panel-derived tumor mutational burden in the context of both tumor-normal and tumor-only sequencing
1272 Probabilistic mixture models improve calibration of panel-derived tumor mutational burden in the context of both tumor-normal and tumor-only sequencing
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

1272 Probabilistic mixture models improve calibration of panel-derived tumor mutational burden in the context of both tumor-normal and tumor-only sequencing

Anaya, Jordan ; John-William Sidhom ; Baras, Alexander

Journal for immunotherapy of cancer, 2022, Vol.10 (Suppl 2), p.A1320-A1321 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
6
P17 Adopting the nominal group technique to understand the use of religious practices and experiences
P17 Adopting the nominal group technique to understand the use of religious practices and experiences
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

P17 Adopting the nominal group technique to understand the use of religious practices and experiences

Anarfi, Ophelia ; Monu, Stella Dzifa ; Mate-Kole, Charles Christopher

BMJ open, 2019, Vol.9 (Suppl 1), p.A20-A20 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
7
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials

Cervera-Carrascon, Victor ; Svane, Inge ; Peltola, Katriina ; Alanko, Tuomo ; Korpisaari, Riitta ; Juteau, Susanna ; Jaakkola, Marjut ; Sormunen, Jorma ; Kononen, Juha ; Steensgaard, Eva Ellebaek ; Monberg, Tine ; Donia, Marco ; Khammari, Amir ; Dreno, Brigitte ; Santos, Joao ; Sorsa, Suvi ; Havunen, Riikka ; Hemminki, Akseli

Journal for immunotherapy of cancer, 2022, Vol.10 (Suppl 2), p.A748-A748 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
8
769 Results from an ongoing open-label, multicenter, phase 1 trial of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors
769 Results from an ongoing open-label, multicenter, phase 1 trial of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

769 Results from an ongoing open-label, multicenter, phase 1 trial of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors

Tapia-Rico, Gonzalo ; Lundy, Joanne ; Richardson, Gary ; Zhao, Niky ; Ebsworth, Karen ; Yue, Huibin ; Miao, Shichiang ; deGoma, Emil ; Jain, Rita ; Schall, Thomas ; Sullivan, Kathleen ; Zhang, Penglie ; de Souza, Paul

Journal for immunotherapy of cancer, 2022, Vol.10 (Suppl 2), p.A800-A800 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
9
526 miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma
526 miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

526 miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma

Challagundla, Kishore ; Pathania, Anup ; Prathipati, Philip ; Srinivas Chava ; Olwenyi, Omalla ; Smith, Oghenetejiri ; Gupta, Subash ; Chaturvedi, Nagendra ; Byrareddy, Siddappa ; Coulter, Don

Journal for immunotherapy of cancer, 2022, Vol.10 (Suppl 2), p.A551-A551 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
10
1155 ONM-501, a polyvalent STING agonist, exhibits anti-tumor efficacy with increased tumor T-cell infiltration in mice and is well tolerated in rats and non-human primates
1155 ONM-501, a polyvalent STING agonist, exhibits anti-tumor efficacy with increased tumor T-cell infiltration in mice and is well tolerated in rats and non-human primates
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

1155 ONM-501, a polyvalent STING agonist, exhibits anti-tumor efficacy with increased tumor T-cell infiltration in mice and is well tolerated in rats and non-human primates

Chen, Zirong ; Miller, Jason ; Li, Wei ; Torres, Katy ; Su, Qingtai ; Huang, Gang ; Yasser Saud O Albaroodi ; Morsch, Rachel ; McElvaney, Teresa ; Stavros, Fiona ; Kruppa, Don ; Zhao, Tian ; Gao, Jinming ; Han, Ruolan

Journal for immunotherapy of cancer, 2022, Vol.10 (Suppl 2), p.A1198-A1198 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (441)
  2. Revistas revisadas por pares (478)

Idioma 

  1. Inglês  (554)
  2. Francês  (16)
  3. Espanhol  (4)
  4. Italiano  (3)
  5. Polonês  (2)
  6. Romeno  (2)
  7. Húngaro  (1)
  8. Alemão  (1)
  9. Holandês  (1)
  10. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.